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Abstract
S100B belongs to a family of calcium-binding proteins implicated in intracellular and extracellular
regulatory activities. This study of serum S100B in primary progressive multiple sclerosis (PPMS) is
based on data obtained from a randomized, controlled trial of Interferon β-1a in subjects with
PPMS. The key questions were whether S100B levels were associated with either disability or MRI
findings in primary progressive MS and whether Interferon β-1a has an effect on their S100B levels.
Serial serum S100B levels were measured using an ELISA method. The results demonstrated that
serum S100B is not related to either disease progression or MRI findings in subjects with primary
progressive MS given Interferon β-1a. Furthermore there is no correlation between S100B levels
and the primary and secondary outcome measures.
Introduction
S100B belongs to a family of calcium-binding proteins
implicated in intracellular and extracellular regulatory
activities [2]. Intracellularly, it exhibits regulatory effects
on cell growth, differentiation, cell shape and energy
metabolism. Extracellularly, S100B stimulates neuronal
survival, differentiation, astrocytic proliferation, neuronal
death via apoptosis, and stimulates (in some cases) or
inhibits (in others) activity of inflammatory cells.
Several studies suggest that S100B has a role in the patho-
genesis of multiple sclerosis (MS). Phenotypically and
functionally similar T cells specific against S100B can be
detected in the peripheral blood of MS patients making
S100B a putative candidate auto-antigen in MS [15]. Fur-
thermore, S100B may act as a cytokine [2,10,11] and in
vitro studies show that, at high levels, S100 can induce the
neuronal expression and secretion of pro-inflammatory
interleukin-6. In addition, elevated levels of S100B have
been detected in the cerebrospinal fluid (CSF) of MS
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patients during acute phases or exacerbations of the
disease [10] and it has therefore been proposed that ele-
vated S100B may be indicative of active cell injury [11].
Interferon-β (IFN-β) is effective in reducing relapse rate in
relapsing-remitting [6,14,17] and secondary progressive
MS [3] but the mechanisms behind the beneficial action
of IFNβ are not fully understood. Two potential sites of
action are on cytokine production [1,4,12] and on the
entry of leukocytes into the CNS [8,9,16,18].
In this clinically negative phase II study [7], we assessed
the effect of IFNβ-1a on serum levels of S100B at 3-month
intervals in subjects with primary progressive MS (PPMS).
The key questions were whether serum S100B levels corre-
lated with disability or MRI findings in patients with
PPMS, and whether IFN-β has an effect on levels of serum
S100B.
Methods
Patients and examination
Fifty patients with PPMS were recruited in a phase II trial
of IFNβ-1a (Avonex®, Biogen) and were assessed three
monthly over a study period of 2 years. Fifteen of these
patients were treated with IFNβ-1a 30µg intramuscularly
(im) weekly (IFN30), 15 received IFNβ-1a 60µg im
weekly (IFN60) and 20 with placebo. IFNβ-1a was
reduced to half dose in 5 subjects receiving 60µg im
weekly, and in 2 subjects receiving IFNβ-1a 30µg im
weekly. Seven subjects withdrew from treatment [7] (see
Figure 1).
Neurological examination was performed at each visit and
disability was measured using Kurtzke's expanded disabil-
ity status scale (EDSS). Progression was defined as a sus-
tained (3 months apart) increase of at least 1.0 on the
EDSS scale between 0 to 5 and 0.5 for subjects with EDSS
score of 5.5 and above.
Fourteen healthy subjects served as controls.
All subjects provided informed consent prior to their
inclusion in the study. This study was approved by the
ethics committee and has therefore been performed with
the ethical standards laid down in the 1964 Declaration of
Helsinki.
Fifty subjects with PPMS were randomised in a phase II trial of Interferon β-1a and were assessed 3 monthly over a 2-year  study period Figure 1
Fifty subjects with PPMS were randomised in a phase II trial of Interferon β-1a and were assessed 3 monthly over a 2-year 
study period. n = number of subjects with PPMS
    Randomized (n=50)
 Placebo  (n=20)  IFN30  (n=15)  IFN60  (n=15)
Treatment withdrawal Treatment withdrawal Treatment withdrawal
(n=2)    (n=1)     (n=4) 
Dose reduction Dose reduction 
(n=2) (n=5)
Follow up 2 years  Follow up 2 years  Follow up 2 years 
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MR imaging and analyses
MRI was performed at baseline and 6 monthly for 2 years.
Only baseline and year 2 data were included in this study.
Brain and spinal cord atrophy, ventricular volume, T1 and
T2 lesion load were measured as described elsewhere [7].
Serum S100B levels
Serum samples were centrifuged and stored at -20°C.
Serum S100B levels were quantified using a modified
ELISA method as previously described by Green et al. [5].
Ninety-six-well plates were coated with 100µl 0.05 M car-
bonate buffer containing 10µl monoclonal anti-S100B
(Affiniti Research Products, Exeter, UK). The plates were
washed with 0.67 M barbitone buffer containing 5 mM
calcium lactate, 0.1% BSA and 0.05% Tween and then
blocked with 2% BSA and washed again. Diluted serum
(1:1) in 0.67 M barbitone buffer containing 5 mM cal-
cium lactate was added in duplicate. After incubation and
wash 0.1% HRP conjugated polyclonal anti-S100B (Dako,
Copenhagen, Denmark) was used as detecting antibody.
The OPD colour reaction was stopped with 1 M hydro-
chloric acid and the absorbance read at 492 and 405 nm.
The antigen concentration was calculated against a stand-
ard curve ranging from 0.01 to 2.5 ng/ml.
Statistical analyses
Median, interquartile range and significance of group dif-
ferences (Mann-Whitney U tests) were evaluated. Changes
of serum level over time were examined using variance
components regression models of serum response varia-
ble on time as predictor, with random subject-specific
intercepts and fixed common slopes. Curvature was
assessed using a quadratic term in time; modification of
curve over time by treatment was assessed using addi-
tional terms for treatment and treatment by time interac-
tion in the model. Two sets of treatment terms were used:
i) indicators of assigned weekly dose ii) average weekly
dose over follow-up (including changes to dose regime)
as continuous variable. Modification of the curve over
time by MRI variable values were similarly examined
using terms for MRI variable and MRI variable by time
interaction.
Direct associations between serum level and MRI/clinical
variables were examined by regression models of 24
month serum on 24 month MRI variable, adjusting for
baseline serum and MRI values (this type of model takes
into account change from baseline), with additional terms
for treatment and treatment by MRI variable interaction,
the latter to assess possible modifications of the relation-
ship by treatment.
Software used were the SPSS software package (version
11.0 for Windows) and Stata 7.0 (Stata Corporation. Stata
Statistical Software: Release 7.0. College Station, Texas,
USA).
Results
Serum S100B between subjects with PPMS and controls
The median and interquartile ranges for all subjects are
described in Table 1. There were no significant differences
between any of the groups in relation to age. When com-
paring S100B levels at baseline of subjects with PPMS and
controls, the difference was not statistically significant (p
= 0.3).
Serum S100B change over time
There was no change over time in the serum S100B levels.
The shape of the serum trajectory did not vary between the
treatment regimes, i.e. placebo vs. IFN30 vs. IFN60.
Table 1: Age and serial serum S100B levels expressed as median (interquartile range). n = number of subjects; mo, months; N/A, non-
applicable.
Control (n = 14) Placebo (n = 20) IFN30 (n = 15) IFN60 (n = 15)
Male:Female 6:8 n = 14 15:5 n = 20 10:5 n = 15 7:8 n = 15
Age (years) 32 (29–44) n = 14 43 (36–51) n = 20 51 (39–53) n = 15 52 (43–54) n = 15
S100B-0mo 0.08 (0.08–0.10) n = 14 0.09 (0.02–0.10) n = 20 0.06 (0.04–0.10) n = 12 0.07 (0.04–0.10) n = 14
S100B-3mo N/A 0.08 (0.05–0.10) n = 20 0.06 (0.05–0.10) n = 15 0.07 (0.04–0.10) n = 14
S100B-6mo N/A 0.10 (0.03–0.20) n = 18 0.07 (0.04–0.10) n = 15 0.07 (0.04–0.10) n = 14
S100B-9mo N/A 0.08 (0.03–0.10) n = 18 0.05 (0.02–0.10) n = 15 0.06 (0.04–0.10) n = 14
S100B-12mo N/A 0.07 (0.03–0.10) n = 17 0.08 (0.05–0.10) n = 15 0.08 (0.04–0.10) n = 14
S100B-15mo N/A 0.07 (0.02–0.10) n = 19 0.07 (0.04–0.10) n = 14 0.09 (0.04–0.10) n = 14
S100B-18mo N/A 0.07 (0.04–0.10) n = 18 0.06 (0.02–0.09) n = 13 0.09 (0.03–0.20) n = 14
S100B-21mo N/A 0.06 (0.05–0.10) n = 18 0.08 (0.04–0.10) n = 14 0.08 (0.04–0.20) n = 13
S100B-24mo N/A 0.07 (0.02–0.10) n = 18 0.07 (0.05–0.10) n = 15 0.06 (0.04–0.10) n = 13Journal of Negative Results in BioMedicine 2004, 3:4 http://www.jnrbm.com/content/3/1/4
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Serum S100B versus Clinical and MRI parameters (Table 2)
There was no evidence that the 24-month serum S100B
values were associated with either changes in the T1 or T2
loads, or ventricular or cord volumes at 24 months, after
adjusting for the baseline values of each subject. There was
no correlation with disease progression on the EDSS.
There was also no evidence that these relationships were
modified by treatment assignment (intention-to-treat
analysis) (Table 2) or the overall average dose, which
included the changes to treatment regime (non-intention-
to-treat analysis) (Table 2).
Discussion
These results suggest that serum S100B levels in patients
with PPMS were not affected by intramuscular IFNβ-1a
and that there was no observable change in S100B over
time. Furthermore, we did not observe any correlation
between S100B levels and clinical disability or between
S100B and quantitative MRI measures.
This study therefore suggests Although there is evidence
that S100B elevation in MS is related to inflammatory
activity [10,11,13], this study has shown that S100B was
not sensitive to disease progression in PPMS. This sup-
ports the view that PPMS is less inflammatory than other
forms of MS and that serum S100B would be ineffective as
a surrogate marker of disease progression in this
subgroup.
It would be valuable to identify surrogate markers of clin-
ical progression in PPMS to aid the development of effec-
tive therapeutic intervention, since clinical trials with a
disability endpoint are very large and resource consum-
ing. It is possible that such markers would need to be less
related to acute inflammation and more dependant on
other neuropathology such as axonal loss and
regeneneration.
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